An Observational Study for Evaluation of for the Prevalence of Cerebrotendinous Xanthomatosis (CTX) Disease (GEN-EYE-II)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04113083 |
|
Recruitment Status :
Terminated
(Due To Covid-19 there were delays in the arrival of patients to the sites. Due to the rare disease in the study population, no patients who met the inclusion/exclusion criteria were found, and the study was terminated early due to these reasons.)
First Posted : October 2, 2019
Last Update Posted : June 15, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The prevalence of CTX in our country is estimated to be 1 / 50.000. The aim of this study is to screen more volunteers by conducting a larger screening from neurology and pediatric metabolism clinics in Turkey.
This observational study was designed retrospectively and prospectively in two stages. In the retrospective section, the patient database and / or patient files will be screened in the neurology and pediatric metabolism clinics and the patients aged 40 and below in the neurology clinics with at least two of the following will be enrolled to the study:
- Ataxia and / or spasticity
- Bilateral cataract (except senile cataract)
- Intellectual limitation
- Non-enhancing hyperintensity on T2 sections in MR imaging of dentate nuclei
- Autosomal recessive transition pattern. (Ex: Relative Marriage)
In the pediatric metabolism centers, cases suspected of CTX and planned to apply the Mignarri Index according to the investigator's opinion will be identified.
| Condition or disease | Intervention/treatment |
|---|---|
| CTX - Cerebrotendinous Xanthomatosis | Other: Blood sampling for cholestanol analysis |
| Study Type : | Observational |
| Actual Enrollment : | 22 participants |
| Observational Model: | Other |
| Time Perspective: | Other |
| Official Title: | An Epidemiological Observational Study for Retrospective and Prospective Evaluation of for the Prevalence of Cerebrotendinous Xanthomatosis (CTX) Disease in Neurology and Pediatric Metabolism Clinics in Turkey |
| Actual Study Start Date : | October 19, 2019 |
| Actual Primary Completion Date : | March 16, 2022 |
| Actual Study Completion Date : | June 10, 2022 |
- Other: Blood sampling for cholestanol analysis
Blood sampling will be performed by Düzen Laboratories group for cholestanol
- Proportion of patients with CTX possibility in Neurology Clinics [ Time Frame: 3 years ]
- Proportion of patients aged 40 years or younger with at least two of the following (2) in patients with a cholestanol test threshold (3.75 mg / mL) in neurology clinics:
- Ataxia and / or spasticity
- Bilateral cataract (except senile cataract)
- Intellectual limitation
- Nonintensitive hyperintensity in T2 sections on MRI of the dentate nucleus
- Forming an autosomal recessive transition pattern. (Ex: Relative Marriage)
- Proportion of patients with CTX possibility in Pediatric Metabolism Clinics [ Time Frame: 3 years ]- Proportion of cases above the cholestanol test threshold (3.75 mg / mL) in pediatric metabolism centers
- Total of Mignarri Suspicion Index (SI) [ Time Frame: 3 Years ]
Mignarri is a suspicion index, composed of weight-ed scores assigned to indicators such as family history and common systemic and neurological features. The indicators were classified as very strong (score 100), strong (50) or moderate (25). The suspicion index will be applied to study population. Early systemic signs such as catamct, diarrhea and neonatal cholestatic jaundice were considered strong indica- tors, together with neurological features such as intellectual impairment, psychiatric disturbances, ataxia, spastic paraparesis and dentate nuclei abnormalities at MRI. Tendon xanthomas were regarded as very strong indicators, as was an affected sibling. A total score 100 warranted serum cholestanol assessment. Elevated cholestanol or a total score 200, with one very strong or four strong indicators, warranted CYP27Al gene analysis. (Reference: Mignarri et al. J Inherit Metab Dis (2014) 37:421-429)
-and physical examination results for patients with high cholestanol levels
- Cholestanol Levels [ Time Frame: 3 Years ]- Cholestanol levels for patients with high cholestanol levels
- Patient demographics [ Time Frame: 3 Years ]
For all screened patients:
• Demographic data
- CTX Family History [ Time Frame: 3 Years ]
For all screened patients:
• CTX family history
- Presence of consangunious marriage [ Time Frame: 3 Years ]
For all screened patients:
• Presence of consanguineous marriage
- Frequency of the systemic findings [ Time Frame: 3 Years ]
For all screened patients:
• Frequency of the following systemic findings:
- Tendon xanthomas
- Chronic diarrhea
- Prolonged neonatal jaundice
- Early osteoporosis
- Frequency of the neurologic findings [ Time Frame: 3 Years ]
For all screened patients:
• Frequency of the following neurological symptoms:
- Cerebellar ataxia
- Spastic paraparesis
- Blateral cataract (except senile cataract)
- Non-enhancing hyperintensity on T2 sections in MR imaging of dentate nuclei
- Intellectual disability
- Psychiatric disorders
- Epilepsy
- Parkinson's
- Polyneuropathy
Biospecimen Retention: Samples Without DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | up to 40 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Inclusion Criteria:
I-1. Giving written informed consent
I-2. Patients in neurology clinics should have been identified with at least two of the following:
- Ataxia and / or spasticity
- Bilateral cataract (except senile cataract)
- Intellectual limitation
- Nonintensitive hyperintensity in T2 sections on MRI of the dentate nucleus
- Forming an autosomal recessive transition pattern. (Ex: Relative Marriage)
I-3. In the pediatric metabolism centers, cases suspected of CTX and planned to apply the Mignarri Index according to the investigator's opinion.
I-4. On the day the patient signed the Informed Consent Form, the patient did not get older than 41 years of age (subjects aged 40 and under will be included in the study)
Exclusion Criteria:
E-1. The patient's ataxia and / or spasticity, cataract, intellectual limitation, and non-contrasted hyperintensity of T2 sections in MR imaging of dentate nuclei with typical MRI findings are due to a known cause other than CTX or other underlying disease.
E-2. The patient has participated in an interventional clinical study in the last 30 days,
E-3. The patient and / or his / her legal representative does not give consent to participate in the study,
E-4. In the opinion of the investigator, the patient is not able to fulfill the working requirements appropriately,
E-5. Pregnancy and / or lactation
E-6. If the patient was 41 years old when included in the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04113083
Show 22 study locations
| Responsible Party: | TRPHARM |
| ClinicalTrials.gov Identifier: | NCT04113083 |
| Other Study ID Numbers: |
TR-CTX-002 |
| First Posted: | October 2, 2019 Key Record Dates |
| Last Update Posted: | June 15, 2022 |
| Last Verified: | June 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Xanthomatosis, Cerebrotendinous Xanthomatosis Lipid Metabolism Disorders Metabolic Diseases Lipid Metabolism, Inborn Errors Metabolism, Inborn Errors |
Genetic Diseases, Inborn Dehydrocholesterols Provitamins Vitamins Micronutrients Physiological Effects of Drugs |